IBM and NIH want to find out if artificial intelligence (AI) can be used to detect people at risk of developing schizophrenia. The International Business Machines announced that it will work with researchers from Mount Sinai School of Medicine, Harvard Medical School, the Northern California Institute for Research and Education, and Stanford University.
The AMP SZ initiative wants to predict outcomes and trajectories and generate risk calculators that can be used in future trials for treatment intervention by leveraging these biomarkers. NIH and BIM aim to prevent psychosis onset progression, mood disorders and anxiety, drug abuse and alcohol, suicidal behavior, and more.
IBM announced that it will contribute to data-driven AU and brain imaging for neurodegenerative and neurodevelopmental disorders. The company also plans to guide and observe the collection of data, including language samples.
"The ... initiative as a whole will be a unique opportunity for IBM to be a leader in the realization the enormous potential of integrating large volumes of data, artificial intelligence, and basic neuroscientific research to help impact mental health," said Guillermo Cecchi, a principal research staff member at IBM.
For more news updates about new biotechs, always keep your tabs open here at TechTimes.
This article is owned by TechTimes,
Written by: Giuliano de Leon.
